Table 1. Characteristics and disease parameters in 54 patients with juvenile dermatomyositis and in 54 controls.
| Characteristics | JDM patients | Controls |
| Females | 32 (59) | 32 (59) |
| Age at symptom onset (years) | 7.7 (1.4–17.3) | NA |
| Age at diagnosis (years) | 8.5 (2.1–19.3) | NA |
| Variables assessed median 16.8 years after disease onset (follow-up) | ||
| Age (years) at follow-up | 22.0 (6.7–55.4) | 22.1 (6.2–55.4) |
| Duration from disease onset (years) | 16.8 (2.0–38.1) | NA |
| CRP (<4 mg/L) | 2.3 (3.3) | 1.4 (3.1) |
| ESR (<17 mm)† | 7.0 (5.7) | 5.7 (4.8) |
| SF 36 PCS‡ (0–100) | 54.3 (26.9–60.9) | 56.9 (32.1–63.7)* |
| CHAQ/HAQ (0–3) | 0 (0–1.38) | NA |
| MDI total (0–40) | 3 (0–13) | NA |
| DAS skin (0–9) | 4 (0–7) | NA |
| DAS muscle (0–11) | 1 (0–8) | NA |
| DAS total (0–20) | 5 (0–13) | NA |
| Prednisolone dosis, cumulative (g) | 10.6 (12.3) | NA |
| Prednisolone or DMARDs | 16 (30) | NA |
| Variables assessed 1 year post- diagnosis | ||
| MDI total (0–40) | 1 (0–7) | NA |
| DAS skin (0–9) | 4 (0–8) | NA |
| DAS muscle (0–11) | 1 (0–7) | NA |
| DAS total (0–20) | 5 (0–15) | NA |
Values are number (%), median (range) or mean (SD). JDM: juvenile dermatomyositis; NA: not applicable; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SF-36 PCS: Short Form 36 physical component Summary; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: disease modifying anti-rheumatic drugs; MDI: Myositis Damage Index; DAS: Disease Activity Score.
*p<0.05.
‡
n = 46 pairs, only assessed in those >13 years;
†
n = 50 pairs.